Abbott Laboratories Stock Jumps on Q2 Earnings and Revenue Beat

Abbott Laboratories (NYSE: ABT) stock rose sharply in pre-market trading Tuesday after the company posted second-quarter financial results that exceeded analyst forecasts. The healthcare giant's shares jumped 4.4% ahead of the market open on the news.

Strong Quarterly Performance

Abbott reported Q2 adjusted earnings per share (EPS) of $1.33 on revenue of $12.79 billion. These figures comfortably beat the consensus estimates from Wall Street, which had projected an EPS of $1.28 and revenue of approximately $12.52 billion, according to Investing.com data.

Driving the positive results, management signaled that sales from its continuous glucose monitoring products, a closely watched metric, are poised to return to double-digit growth. The quarter also included the first full contribution from the Exact Sciences acquisition, completed in March 2026, which is expected to add about $3 billion in incremental cancer diagnostics sales for the year.

Ad

Market Reaction and Context

The stock's advance is a company-specific catalyst, standing in contrast to a weaker broader market. In pre-market activity, the S&P 500 was down 0.3% and the Nasdaq was off 0.9%. The move also comes after a period of underperformance for Abbott, with its stock trading significantly below its 52-week high of $137.49, making the positive earnings surprise more impactful for investors.

The strong report follows a series of positive analyst notes leading up to the release. Firms including Benchmark, Bank of America, and RBC Capital had all maintained Buy ratings on the stock, anticipating solid performance.